A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862
This study is recruiting at 13 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Exelixis
- Last updated on ClinicalTrials.gov
- September 5, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 3
- Exelixis Clinical Site #15 · Jacksonville, FL
- Exelixis Clinical Site #8 · Orlando, FL
- Exelixis Clinical Site #16 · Tampa, FL
Minnesota · 1
- Exelixis Clinical Site #14 · Rochester, MN
New Jersey · 1
- Exelixis Clinical Site #9 · New Brunswick, NJ
New York · 1
- Exelixis Clinical Site #5 · New York, NY
Ohio · 1
- Exelixis Clinical Site #7 · Cleveland, OH
Oklahoma · 1
- Exelixis Clinical Site #13 · Oklahoma City, OK
Tennessee · 2
- Exelixis Clinical Site #11 · Germantown, TN
- Exelixis Clinical Site #6 · Nashville, TN
Texas · 3
- Exelixis Clinical Site #4 · Austin, TX
- Exelixis Clinical Site #1 · Houston, TX
- Exelixis Clinical Site #3 · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.